Thomas Triomphe News Today

Unless We the People stop them, climate fanatics like billionaire eugenicist Bill Gates are planning to inject you and your family with climate change and global warming “vaccines.” Right now, they are already injecting meat animals with climate jabs, claiming these are necessary to keep the animals “safe” from fictitious diseases. Eventually, they will proceed […]

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract...

Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS, expectations were $0.96.

SNY earnings call for the period ending December 31, 2023.

SNY earnings call for the period ending December 31, 2023.

Sanofi (NASDAQ:SNY) Q3 2023 Earnings Call Transcript October 27, 2023 Eva Schaefer-Jansen: [starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded. 2023 results followed by a Q&A session. As usual, you can find the slides to this call on the investors page […]

Eva Schaefer-Jansen: [starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded. 2023 results followed by a Q&A session.

SNY earnings call for the period ending September 30, 2023.

Kids younger than 5 are at risk for severe dengue symptoms, including dehydration and shock.

Bsip/Universal Images Group via Getty Images(WASHINGTON) -- A new immunization to protect infants from respiratory syncytial virus, or RSV was approved by the Centers for Disease Control and Prevention on Thursday. The approved drug called nirsevimab, which will be marketed in the U.S. by Sanofi as Beyfortus, was recommended unanimously by the CDCs Advisory Committee on Immunization Practice for all children under 8 months old and signed off on by CDC director Dr. Mandy Cohen, the last step in t...